Acadia Pharmaceuticals earnings were $226.5M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest ACAD earnings report on Dec 31, 2024 announced Q4 2024 earnings of $143.7M, up 338.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ACAD reported annual earnings of $226.5M, with -469.5% growth. The next ACAD earnings date is May 6, 2025.
Acadia Pharmaceuticals Earnings Reports & History FAQ
What were Acadia Pharmaceuticals's earnings last quarter?
On ACAD's earnings call on Invalid Date, Acadia Pharmaceuticals (NASDAQ: ACAD) reported Q4 2024 earnings per share (EPS) of $0.87, up 210.71% year over year. Total ACAD earnings for the quarter were $143.74 million. In the same quarter last year, Acadia Pharmaceuticals's earnings per share (EPS) was $0.28.
The next ACAD earnings date is Invalid Date. Add ACAD to your watchlist to be reminded of Acadia Pharmaceuticals's next earnings date.
Is Acadia Pharmaceuticals profitable or losing money?
As of the last Acadia Pharmaceuticals earnings report, Acadia Pharmaceuticals is currently profitable. Acadia Pharmaceuticals's net profit (also called net income) for the twelve months ending Dec 31, 2024 was $226.45 million, a 469.5% decrease year over year.
What was ACAD's earnings growth in the past year?
As of Acadia Pharmaceuticals's earnings date in Invalid Date, Acadia Pharmaceuticals's earnings has grown year over year. ACAD earnings in the past year totalled $226.45 million.
What are Acadia Pharmaceuticals's earnings expectations?
The current EPS estimate for Acadia Pharmaceuticals's earnings report in Invalid Date is $0.05.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.